S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
NYSE:LH

Laboratory Co. of America - LH Stock Forecast, Price & News

$258.74
-0.37 (-0.14%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$257.30
$262.68
50-Day Range
$213.86
$262.19
52-Week Range
$212.40
$317.17
Volume
423,348 shs
Average Volume
847,671 shs
Market Capitalization
$23.99 billion
P/E Ratio
12.38
Dividend Yield
1.11%
Price Target
$299.75

Laboratory Co. of America MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
15.8% Upside
$299.75 Price Target
Short Interest
Healthy
2.25% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.16mentions of Laboratory Co. of America in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$8.82 M Sold Last Quarter
Proj. Earnings Growth
-10.49%
From $20.21 to $18.09 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

212th out of 1,112 stocks

Medical Laboratories Industry

6th out of 27 stocks

LH stock logo

About Laboratory Co. of America (NYSE:LH) Stock

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

Laboratory Co. of America Price Performance

NYSE:LH traded down $0.37 during trading hours on Thursday, reaching $258.74. 423,348 shares of the company's stock were exchanged, compared to its average volume of 847,640. The stock has a market cap of $23.99 billion, a PE ratio of 12.38 and a beta of 1.03. Laboratory Co. of America has a one year low of $212.40 and a one year high of $317.17. The firm has a fifty day moving average of $241.47 and a 200-day moving average of $256.10. The company has a current ratio of 1.90, a quick ratio of 1.74 and a debt-to-equity ratio of 0.52.

Laboratory Co. of America (NYSE:LH - Get Rating) last released its quarterly earnings results on Thursday, July 28th. The medical research company reported $4.95 EPS for the quarter, topping analysts' consensus estimates of $4.60 by $0.35. The business had revenue of $3.70 billion for the quarter, compared to analyst estimates of $3.76 billion. Laboratory Co. of America had a return on equity of 22.39% and a net margin of 12.67%. Laboratory Co. of America's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the prior year, the company earned $6.13 EPS. On average, equities research analysts predict that Laboratory Co. of America will post 20.21 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Thursday, August 18th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.11%. The ex-dividend date of this dividend is Wednesday, August 17th. Laboratory Co. of America's dividend payout ratio (DPR) is currently 13.78%.

Analysts Set New Price Targets

A number of brokerages have weighed in on LH. Mizuho reduced their price target on Laboratory Co. of America from $354.00 to $323.00 in a research report on Wednesday, May 4th. Deutsche Bank Aktiengesellschaft reduced their price target on Laboratory Co. of America from $294.00 to $265.00 in a research report on Tuesday, May 3rd. Wells Fargo & Company reduced their price target on Laboratory Co. of America from $290.00 to $235.00 and set an "equal weight" rating for the company in a research report on Monday, April 25th. Truist Financial reduced their price target on Laboratory Co. of America from $350.00 to $320.00 in a research report on Friday, April 29th. Finally, Robert W. Baird boosted their price objective on Laboratory Co. of America from $295.00 to $297.00 and gave the stock an "outperform" rating in a research report on Thursday, August 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Laboratory Co. of America presently has an average rating of "Moderate Buy" and a consensus target price of $299.75.

Insider Activity

In related news, CFO Glenn A. Eisenberg sold 32,100 shares of the firm's stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $253.94, for a total transaction of $8,151,474.00. Following the sale, the chief financial officer now owns 52,158 shares of the company's stock, valued at approximately $13,245,002.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Glenn A. Eisenberg sold 32,100 shares of the firm's stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $253.94, for a total transaction of $8,151,474.00. Following the sale, the chief financial officer now owns 52,158 shares of the company's stock, valued at approximately $13,245,002.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Peter J. Wilkinson sold 2,576 shares of the firm's stock in a transaction on Monday, August 1st. The stock was sold at an average price of $258.40, for a total value of $665,638.40. Following the sale, the chief accounting officer now directly owns 1,887 shares in the company, valued at approximately $487,600.80. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by company insiders.

Receive LH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Laboratory Co. of America and its competitors with MarketBeat's FREE daily newsletter.

LH Stock News Headlines

Laboratory Co. of America (NYSE:LH) Price Target Cut to $308.00
Labcorp to Spin Off Clinical-Development Business
See More Headlines
Receive LH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Laboratory Co. of America and its competitors with MarketBeat's FREE daily newsletter.

LH Company Calendar

Ex-Dividend for 6/9 Dividend
5/18/2022
Dividend Payable
6/09/2022
Last Earnings
7/28/2022
Today
8/11/2022
Ex-Dividend for 9/9 Dividend
8/17/2022
Dividend Payable
9/09/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Health Care Services
Sector
Medical
CUSIP
50540R40
Employees
75,500
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$299.75
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$235.00
Forecasted Upside/Downside
+15.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$2.38 billion
Pretax Margin
16.36%

Debt

Sales & Book Value

Annual Sales
$16.12 billion
Cash Flow
$37.72 per share
Book Value
$112.20 per share

Miscellaneous

Free Float
92,413,000
Market Cap
$23.99 billion
Optionable
Optionable
Beta
1.03

Social Links















LH Stock - Frequently Asked Questions

Should I buy or sell Laboratory Co. of America stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LH shares.
View LH analyst ratings
or view top-rated stocks.

What is Laboratory Co. of America's stock price forecast for 2022?

6 analysts have issued 1-year target prices for Laboratory Co. of America's stock. Their LH share price forecasts range from $235.00 to $350.00. On average, they anticipate the company's share price to reach $299.75 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price.
View analysts price targets for LH
or view top-rated stocks among Wall Street analysts.

How have LH shares performed in 2022?

Laboratory Co. of America's stock was trading at $314.21 at the beginning of 2022. Since then, LH stock has decreased by 17.7% and is now trading at $258.74.
View the best growth stocks for 2022 here
.

When is Laboratory Co. of America's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our LH earnings forecast
.

How were Laboratory Co. of America's earnings last quarter?

Laboratory Co. of America Holdings (NYSE:LH) announced its earnings results on Thursday, July, 28th. The medical research company reported $4.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.60 by $0.35. The medical research company earned $3.70 billion during the quarter, compared to analysts' expectations of $3.76 billion. Laboratory Co. of America had a trailing twelve-month return on equity of 22.39% and a net margin of 12.67%. The company's quarterly revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the business earned $6.13 earnings per share.
Read the conference call transcript
.

How often does Laboratory Co. of America pay dividends? What is the dividend yield for Laboratory Co. of America?

Laboratory Co. of America declared a quarterly dividend on Thursday, July 14th. Shareholders of record on Thursday, August 18th will be given a dividend of $0.72 per share on Friday, September 9th. This represents a $2.88 annualized dividend and a dividend yield of 1.11%. The ex-dividend date is Wednesday, August 17th.
Read our dividend analysis for LH
.

Is Laboratory Co. of America a good dividend stock?

Laboratory Co. of America (NYSE:LH) pays an annual dividend of $2.88 per share and currently has a dividend yield of 1.11%. The dividend payout ratio is 13.78%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LH will have a dividend payout ratio of 15.92% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LH.

What guidance has Laboratory Co. of America issued on next quarter's earnings?

Laboratory Co. of America issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $19.00-$21.25 for the period, compared to the consensus earnings per share estimate of $19.70. The company issued revenue guidance of $15.15 billion-$15.80 billion, compared to the consensus revenue estimate of $15.31 billion.

What is Adam Schechter's approval rating as Laboratory Co. of America's CEO?

143 employees have rated Laboratory Co. of America Chief Executive Officer Adam Schechter on Glassdoor.com. Adam Schechter has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Laboratory Co. of America own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Co. of America investors own include Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Pfizer (PFE), Johnson & Johnson (JNJ), NVIDIA (NVDA), Abbott Laboratories (abt), AbbVie (ABBV), Alibaba Group (BABA) and Amgen (AMGN).

What is Laboratory Co. of America's stock symbol?

Laboratory Co. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

Who are Laboratory Co. of America's major shareholders?

Laboratory Co. of America's stock is owned by many different institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (2.05%), Veritas Investment Partners UK Ltd. (1.02%), Cooke & Bieler LP (0.60%), Franklin Resources Inc. (0.46%), Sumitomo Mitsui Trust Holdings Inc. (0.45%) and Deutsche Bank AG (0.45%). Insiders that own company stock include Amy B Summy, Brian J Caveney, David P King, Der Vaart Sandra D Van, Der Vaart Sandra D Van, Dwight Gary Gilliland, Glenn A Eisenberg, Jean-Luc Belingard, Judith C Seltz, Kerrii B Anderson, Lance Berberian, Lisa J Uthgenannt, Mark S Schroeder, Mark S Schroeder, Paul R Kirchgraber, Peter J Wilkinson, Peter M Neupert and R Sanders Williams.
View institutional ownership trends
.

How do I buy shares of Laboratory Co. of America?

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Laboratory Co. of America's stock price today?

One share of LH stock can currently be purchased for approximately $258.74.

How much money does Laboratory Co. of America make?

Laboratory Co. of America (NYSE:LH) has a market capitalization of $23.99 billion and generates $16.12 billion in revenue each year. The medical research company earns $2.38 billion in net income (profit) each year or $20.90 on an earnings per share basis.

How many employees does Laboratory Co. of America have?

The company employs 75,500 workers across the globe.

Does Laboratory Co. of America have any subsidiaries?

The following companies are subsidiares of Laboratory Co. of America: 1957285 Ontario Inc. dba Quality Underwriting Services, 2089729 Ontario Inc., 2248848 Ontario Inc., 3065619 Nova Scotia Company, 3257959 Nova Scotia Company, 8165335 Canada Inc., 8348596 Canada Inc., 896988 Ontario Limited, 9279-3280 Quebec Inc., Accupath Diagnostic Laboratories Inc., Assets of Pathology Inc, Beacon LBS IPA Inc., Beacon Laboratory Benefit Solutions Inc., CannAmm GP Inc., CannAmm Limited Partnership, Center for Disease Detection International, Center for Disease Detection LLC, Centrex Clinical Laboratories Inc., Chiltern, Clearstone Central Laboratories (U.S.) Inc., Clearstone Holdings (International) Ltd., Clipper Holdings Inc., Colorado Coagulation Consultants Inc., Colorado Laboratory Services LLC, Correlagen Diagnostics Inc., Covance Inc., Curalab Inc., Cytometry Associates Inc., Czura Thornton (Hong Kong) Limited, DCL Acquisition Inc., DCL Medical Laboratories LLC, DCL Sub LLC, DIANON Systems Inc., DL Holdings Limited Partnership, Decision Diagnostics L.L.C. (aka DaVinici/Medicorp LLC), Diagnostic Services Inc., DynaLifeDX, Dynacare - Gamma Laboratory Partnership, Dynacare Company, Dynacare G.P. Inc., Dynacare Holdco LLC, Dynacare Laboratories Inc., Dynacare Laboratories Limited Partnership, Dynacare Northwest Inc., Dynacare Realty Inc., DynalifeDX Infrastructure Inc., Envigo's nonclinical contract research services business, Esoterix Genetic Counseling LLC, Esoterix Genetic Laboratories LLC, Esoterix Inc., Execmed Health Services Inc., FirstSource Laboratory Solutions Inc., GDML Medical Laboratories Inc, Gamma Dynacare Central Medical Laboratories GP Inc., Gamma Dynacare Central Medical Laboratory Limited Partnership, HHLA Lab-In-An-Envelope LLC, Health Testing Centers Inc., Health Trans Services Inc., Home Healthcare Laboratory of America LLC, IDX Pathology Inc., Impact Genetics Corporation, Impact Genetics Inc., Kaleida LabCorp LLC, Lab Delivery Service of New York City Inc., LabCorp BVBA, LabCorp Belgium Holdings Inc., LabCorp Central Laboratories (Canada) Inc., LabCorp Central Laboratories (China) Inc., LabCorp Colorado Inc., LabCorp Development Company, LabCorp Employer Services Inc., LabCorp Health System Diagnostics LLC, LabCorp Indiana Inc., LabCorp Japan G.K., LabCorp Limited, LabCorp Michigan Inc., LabCorp Nebraska Inc., LabCorp Neon Ltd., LabCorp Neon Switzerland S.à.r.l., LabCorp Specialty Testing Billing Service Inc., LabCorp Specialty Testing Group Inc., LabCorp Staffing Solutions Inc., LabCorp Tennessee LLC, LabCorp UK Holdings Ltd., LabWest Inc., Laboratoire Bio-Medic Inc., Laboratory Corporation of America, Lifecodes Corporation, LipoScience Inc., Litholink Corporation, MEDTOX Scientific Inc., MNG Laboratories, MedAxio Insurance Medical Services GP Inc., MedAxio Insurance Medical Services LP, Medical Neurogenitics LLC, Medtox Diagnostics Inc., Medtox Laboratories Inc., Monogram Biosciences Inc., Monogram Biosciences UK Limited, Myriad Autoimmune’s Vectra Testing Business, NWT Inc., National Genetics Institute, New Brighton Business Center LLC, New Imaging Diagnostics LLC, New Molecular Diagnostics Ventures LLC, Orchid Cellmark ULC, Ovia Health, PA Labs Inc., Paclab LLC, Path Lab Incorporated, Pathology Associates Medical Lab LLC, Pee Dee Pathology Associates Inc., Personal Genome Diagnostics Inc., Persys Technology Inc., Pixel by LabCorp, Princeton Diagnostic Laboratories of America Inc., Protedyne Corporation, SW/DL LLC, Saint Josephs-PAML LLC, Sequenom Biosciences (India) Pvt. Ltd., Sequenom Inc, Sequenom Inc., Tandem Labs Inc., Toxikon Corporation, Tri-Cities Laboratory LLC, Viro-Med Laboratories Inc., Visiun, and Yakima Medical Arts Inc..
Read More

When was Laboratory Co. of America founded?

Laboratory Co. of America was founded in 1995.

How can I contact Laboratory Co. of America?

Laboratory Co. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The official website for the company is www.labcorp.com. The medical research company can be reached via phone at (336) 229-1127, via email at investor@labcorp.com, or via fax at 336-513-4510.

This page (NYSE:LH) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.